Type(s) of Cancer
Breast
Breast
Study Phase
Phase 3
Study Completion Date
August 2012
August 2012
NCT00265759Uploaded 10-23-2017
Available for Download
PDS UID: Breast_Allianc_2006_216
A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Files:
PROTOCOLZ1031Prot_06Apr2015.pdf
CRFZ1031 A7 CRFS 08-09-10.pdf
DATA DICTIONARYz1031_datadictionary.docx
DATA (ACTIVE ARM)NCT00265759.csv